Table 1.
Patient characteristics (n = 69).
| Variable | Study population |
|---|---|
| Age, years | |
| Median (range) | 61 (32–81) |
| Gender, n (%) | |
| Male | 42 (61) |
| Female | 27 (39) |
| Performance status, n (%) | |
| 0, 1 | 63 (91) |
| 2 | 2 (3) |
| 3 | 4 (6) |
| Primary site of malignancy, n (%) | |
| Head and neck | 2 (3) |
| Lung | 1 (1) |
| Breast | 2 (3) |
| Esophageal | 18 (26) |
| Genitourinary | 46 (67) |
| Chemotherapy regimen, dose (mg/m2), and days | |
| F500D1-2/L30-35D1-2/G1000/P50 | 39 (57) |
| F500D1-2/L30-35D1-2/E100/P50 | 1 (1) |
| F500D1-2/L30-35D1-2/V30/P50 | 4 (6) |
| F500D1-2/L30-35D1-2/P50 | 7 (10) |
| FP | 18 (26) |
| F1000D1-4/P100 | 1 |
| F1000D1-4/P75 | 14 |
| F1000D1-3/P75 | 1 |
| F1000D1-3/P60 | 1 |
| F660D1-4/P50 | 1 |
Abbreviations: F: 5-fluorouracil; L: Leucovorin; P: Cisplatin; E: Etoposide; G: Gemcitabine; V: Vinorelbine; D: Day.